Lyell Immunopharma (LYLE) is positioned for significant upside due to its ronde-cel therapy, which demonstrates best-in-class durability and safety in treating relapsed/refractory large B-cell lymphoma (LBCL). Despite trading near cash value, the market undervalues its pipeline, which includes advanced pivotal trials and promising early efficacy signals. Ronde-cel’s dual targeting of CD19/CD20 and CD62L+ enrichment contribute to durable responses, low severe toxicity, and potential outpatient use. Key upcoming catalysts include data from the PiNACLE trial expected in the second half of 2026 and a cash runway extending to the third quarter of 2027, which could drive a re-rating of the company’s valuation if executed successfully.
Strategy CEO Phong Le addressed concerns about a forced Bitcoin sell-off, stating it is unlikely despite the company's $3.5 billion preferred securities maturing in 2028. The company holds 845,256 BTC, the largest corporate Bitcoin reserve, and recen...
Binance founder Changpeng Zhao (CZ) remains optimistic about a long-term crypto super cycle, despite Bitcoin's recent price volatility and trading within a narrow range around $60,000 to $64,000. CZ acknowledges the difficulty in predicting exact mar...
Kraken is preparing to introduce a regulated perpetual futures product for US traders through its platform Bitnomial. This move aims to bring one of the largest cryptocurrency derivatives products under US regulatory oversight by the Commodity Future...
The US government has identified 16 minerals it produces none of, making the country 100% reliant on imports for these critical materials, which poses national security and economic risks. Financial expert Jim Rickards highlights this dependency, esp...
Litecoin's price has entered a significant Fibonacci support zone, historically linked to accumulation phases, signaling potential long-term value despite short-term weakness. Whale and shark wallets holding over 10,000 LTC have increased by 7% in fi...
